CCN2 and diabetic cardiomyopathy: In addition, CTS administration could effectively attenuate diabetic cardiomyopathy associated cardiac fibrosis by reducing matrix metalloproteinase-9 (MMP-9) and connective tissue growth factor (CTGF) production via inhibiting STAT3 activity [10].